Skip to main content

Table 2 Clinicopathologic Features of 119 HPV16-Positive Squamous Cell Carcinoma Cases with European Variants

From: HPV16 variant lineage, clinical stage, and survival in women with invasive cervical cancer

TRAIT CATEGORY 16-EP (%1)
n = 52
16-EV (%1)
n = 20
16-EV-G (%1)
n = 47
Total (%2)
n = 119
P-VALUE3
  Non-keratinizing 26 (41.9) 12 (19.4) 24 (38.7) 62 (57.4)  
CELL TYPE Keratinizing 21 (45.7) 5 (10.9) 20 (43.5) 46 (42.6) 0.53
  Squamous, NOS4 5 - 3 - 3 - 11 -  
AGE GROUP 20-40 15 (37.5) 5 (12.5) 20 (50.0) 40 (33.6)  
  41-50 20 (45.5) 11 (25.0) 13 (29.5) 44 (37.0) 0.26
  51-72 17 (48.6) 4 (11.4) 14 (40.0) 35 (29.4)  
RACE White 44 (45.8 15 (15.6) 35 (38.5) 94 (76.1)  
  Black 2 (50.0) 2 (50.0) 0 4 (3.4) 0.07
  Hispanic 2 (28.6) 0 5 (71.4) 7 (5.9)  
  Native American 3 (30.0) 1 (10.0) 6 (60.0) 10 (8.5)  
  Asian 1 (50.0) 1 (50.0) 0 2 (1.7)  
  Other 0 - 1 (100) 0 1 (0.8)  
  ND5 0 - 0 - 1 - 1 -  
  1A 6 (42.9) 2 (14.3) 6 (42.9) 14 (12.2)  
STAGE (FIGO) 1B1 16 (44.4) 8 (22.2) 12 (33.3) 36 (31.3) 0.75
  1B2 4 (28.6) 3 (21.4) 7 (50.0) 14 (12.2)  
  2 10 (45.5) 1 (4.5) 11 (50.0) 22 (19.1)  
  3 9 (50.0) 3 (16.7) 6 (33.3) 18 (15.6)  
  4 5 (45.5) 3 (27.3) 3 (27.3) 11 (9.6)  
  Recurrent/Unstaged 2 - 0 - 2 - 4 -  
  0 4 (80.0) 0 - 1 (20.0 5 (4.3)  
GRAVIDITY 1-3 24 (35.8) 11 (16.4) 32 (47.8) 67 (57.8) 0.18
  >3 22 (50.0) 9 (20.5) 13 (29.5) 44 (37.9)  
  ND5 2 - 0 - 1 - 3 -  
PARAMETRIA6 Negative 20 (43.5) 8 (17.4) 18 (39.1) 46 (53.5)  
  Positive 19 (47.5) 6 (15.0) 15 (37.5) 40 (46.6) 0.92
  ND 13 - 6 - 14 - 33 -  
Table 2 (cont'd)       
  <1 6 (40.0) 2 (13.3) 7 (46.7) 15 (14.7)  
TUMOR SIZE6 (cm) 1-4 18 (46.2) 7 (17.9) 14 (35.9) 39 (38.2) 0.96
  >4 21 (43.8) 7 (14.6) 20 (41.7) 48 (47.1)  
  ND 7 - 4 - 6 - 17 -  
  < 3 3 (23.1) 2 (15.4) 8 (61.5) 13 (22.0)  
INVASION DEPTH 7 3.1 - 5.0 5 (62.5) 0 3 (37.5) 8 (13.3) 0.24
(mm) >5 19 (50.0) 7 (18.4) 12 (31.6) 38 (64.4)  
  ND 25 - 11 - 24 - 60 -  
  Positive 15 (40.5) 6 (16.2) 16 (43.2) 37 (59.7)  
VSI7 Negative 12 (48.0) 3 (12.0) 10 (40.0) 25 (40.3) 0.83
  ND 25 - 11 - 21 - 57 -  
RESECTION Positive 7 (63.6) 1 (9.1) 3 (27.3) 11 (19.3)  
MARGINS7 Negative 19 (41.3) 8 (17.4) 19 (41.3) 46 (80.7) 0.49
  ND 26 - 11 - 25 - 65 -  
  Negative 20 (47.6) 4 (9.5) 18 (42.9) 42 (49.4)  
LN STATUS8 Positive 18 (41.9) 8 (18.6) 17 (39.5) 43 (50.6) 0.55
  ND 14 - 8 - 12 - 34 -  
  NED 34 42.5) 13 (16.3) 33 (41.3) 80 (67.2)  
STATUS9 DOD 18 46.2) 7 (17.9) 14 (35.9) 39 (32.8) 0.87
  1. 1: Percentage calculated across.
  2. 2: Percentage calculated down.
  3. 3: Fisher's exact test
  4. 4: Squamous, NOS: Women with very small tumors or tiny biopsies were difficult categorize as to cell type and were not included in these analyses.
  5. 5: ND: No data available
  6. 6: Tumor size and parametrial assessment were determined by pathologic evaluation of a radical hysterectomy or as part of a clinical staging procedure.
  7. 7: Depth of invasion, margin status and status of vascular space invasion were available only for women with early stage tumors who had a conization or hysterectomy.
  8. 8: Lymph node dissections were routinely performed as part of radical hysterectomy. It is not standard for higher stage women although cervical biopsy with lymph node dissection was performed for some higher stage women.
  9. 9: Status: NED = No evidence of cervical cancer; DOD = Dead of cervical cancer